Clinical trial registry record

Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Withdrawn.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 15, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05664893
Last registry update
April 15, 2026
Status
Withdrawn
Phase
Phase 1, Phase 2
Sponsor
Centre Antoine Lacassagne
Enrollment
0
Countries
France
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NA · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
0
Population
FEMALE · 70 Years
Duration
2023-06-26 to 2026-03-26
Intervention
Ribociclib Oral Tablet
Comparator
Not reported
Outcomes measured
Phase I : determination of Maximal Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) of Ribociclib — Phase…; Phase II : evaluation of the efficacy of Ribociclib in association with hormone therapy and hypofractionated radiothera…; overall survival — 24 months; overall survival — 60 months; progression free survival — 24 months; progression free survival — 60 months; quality of Life (European Organisation for Research and Treatment of Cancer quality of life questionnaire C30) — 60 mon…; quality of Life (ELDERLY CANCER PATIENTS14) — 60 months; compliance to Ribociclib — 24 months; medical health status — 60 months; psychosocial health status — 60 months; functional health status — 60 months; overall tolerance of ribociclib using V5.0 Common Terminology Criteria for Adverse Events scale — 25 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON